{"id":"W3032812050","doi":"10.1200/jco.2020.38.15_suppl.9574","title":"Nazartinib (EGF816) in patients with treatment-naïve <i>EGFR</i>-mutant non-small cell lung cancer (NSCLC): Updated phase II results.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rash; Internal medicine; Clinical endpoint; Phases of clinical research; non-small cell lung cancer (NSCLC); Gastroenterology; Lung cancer; Progression-free survival; Progressive disease; Brain metastasis; Adverse effect; Surgery; Oncology; Cancer; Metastasis; Toxicity; Overall survival; Clinical trial; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001649972,0.0005280906,0.001022492,0.0003894214,0.0001332359,0.0006383489,0.0005928153,0.000391856,0.001065357],"category_scores_gemma":[0.000879499,0.0002353583,0.0007272484,0.000477458,0.0001506609,0.0004643985,0.0002142102,0.0008650318,0.0003239058],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004879329,"about_ca_system_score_gemma":0.0006387639,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001113749,"about_ca_topic_score_gemma":0.004346854,"domain_scores_codex":[0.9996517,0.000142633,0.000049404,0.00003921197,0.00007588589,0.00004111923],"domain_scores_gemma":[0.9994831,0.0001006717,0.0002344881,0.00003027071,0.00006434858,0.00008704884],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1658401,0.006303894,0.06638876,0.004345241,0.007528093,0.0005546912,0.0003179354,0.003993603,0.06229718,0.0002472312,0.01568639,0.6664969],"study_design_scores_gemma":[0.2239979,0.2257813,0.42503,0.0008319527,0.01540354,0.005169995,0.0001923384,0.004826368,0.02291321,0.0004783762,0.07518874,0.0001862995],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9102376,0.06889809,0.001696693,0.00104378,0.0002082706,0.002260258,0.007819542,0.000350276,0.007485453],"genre_scores_gemma":[0.9579124,0.02167793,0.002581229,0.001221018,0.0001676647,0.0009453183,0.01354814,0.00004480183,0.001901453],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001649972,"threshold_uncertainty_score":0.008726001,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05481077897376951,"score_gpt":0.4509650800884538,"score_spread":0.3961543011146842,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}